Impact of Duodopa on Quality of Life in Advanced Parkinson's Disease: A UK Case Series
Treatment options in advanced Parkinson’s disease (PD) include subcutaneous apomorphine, pallidal or subthalamic nucleus Deep Brain Stimulation (DBS), or levodopa/carbidopa intestinal gel (LCIG/Duodopa). In this study, we describe the outcome of 12 PD patients with PD related complications started o...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2013-01-01
|
| Series: | Parkinson's Disease |
| Online Access: | http://dx.doi.org/10.1155/2013/362908 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832556056259067904 |
|---|---|
| author | T. Foltynie C. Magee C. James G. J. M. Webster A. J. Lees P. Limousin |
| author_facet | T. Foltynie C. Magee C. James G. J. M. Webster A. J. Lees P. Limousin |
| author_sort | T. Foltynie |
| collection | DOAJ |
| description | Treatment options in advanced Parkinson’s disease (PD) include subcutaneous apomorphine, pallidal or subthalamic nucleus Deep Brain Stimulation (DBS), or levodopa/carbidopa intestinal gel (LCIG/Duodopa). In this study, we describe the outcome of 12 PD patients with PD related complications started on LCIG, with respect to their quality of life measured by a disease specific validated
scale—the PDQ39, together with diaries recording time spent “On,” “Off,” “Dyskinetic,”
or “Asleep.” At the time of latest follow up, improvements were observed in both the PDQ39 Summary index as well as diary reports of PD symptom control following introduction of LCIG, supporting its use in well selected patients. The use of a trial period of LCIG via naso-jejunal administration allows objective evaluation of improvement in PD symptom control in advance of the placement of the more invasive percutaneous jejunostomy procedure. The decision to embark on LCIG, apomorphine or DBS should be supported by input from centres with experience of all 3 approaches. Since LCIG is an expensive option, development of the most appropriate future commissioning of this therapy in the absence of Class 1 evidence requires careful scrutiny of the outcomes of its use in a broad range of published series. |
| format | Article |
| id | doaj-art-377103f270d9400a998cb5ce700aad3c |
| institution | Kabale University |
| issn | 2090-8083 2042-0080 |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Parkinson's Disease |
| spelling | doaj-art-377103f270d9400a998cb5ce700aad3c2025-02-03T05:46:31ZengWileyParkinson's Disease2090-80832042-00802013-01-01201310.1155/2013/362908362908Impact of Duodopa on Quality of Life in Advanced Parkinson's Disease: A UK Case SeriesT. Foltynie0C. Magee1C. James2G. J. M. Webster3A. J. Lees4P. Limousin5Sobell Department of Motor Neuroscience, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UKNational Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UKNational Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UKDepartment of Gastroenterology, University College Hospital NHS Trust, 235 Euston Road, London NW1 2BU, UKReta Lila Weston Institute, 1 Wakefield Street, London WC1N 1PJ, UKSobell Department of Motor Neuroscience, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UKTreatment options in advanced Parkinson’s disease (PD) include subcutaneous apomorphine, pallidal or subthalamic nucleus Deep Brain Stimulation (DBS), or levodopa/carbidopa intestinal gel (LCIG/Duodopa). In this study, we describe the outcome of 12 PD patients with PD related complications started on LCIG, with respect to their quality of life measured by a disease specific validated scale—the PDQ39, together with diaries recording time spent “On,” “Off,” “Dyskinetic,” or “Asleep.” At the time of latest follow up, improvements were observed in both the PDQ39 Summary index as well as diary reports of PD symptom control following introduction of LCIG, supporting its use in well selected patients. The use of a trial period of LCIG via naso-jejunal administration allows objective evaluation of improvement in PD symptom control in advance of the placement of the more invasive percutaneous jejunostomy procedure. The decision to embark on LCIG, apomorphine or DBS should be supported by input from centres with experience of all 3 approaches. Since LCIG is an expensive option, development of the most appropriate future commissioning of this therapy in the absence of Class 1 evidence requires careful scrutiny of the outcomes of its use in a broad range of published series.http://dx.doi.org/10.1155/2013/362908 |
| spellingShingle | T. Foltynie C. Magee C. James G. J. M. Webster A. J. Lees P. Limousin Impact of Duodopa on Quality of Life in Advanced Parkinson's Disease: A UK Case Series Parkinson's Disease |
| title | Impact of Duodopa on Quality of Life in Advanced Parkinson's Disease: A UK Case Series |
| title_full | Impact of Duodopa on Quality of Life in Advanced Parkinson's Disease: A UK Case Series |
| title_fullStr | Impact of Duodopa on Quality of Life in Advanced Parkinson's Disease: A UK Case Series |
| title_full_unstemmed | Impact of Duodopa on Quality of Life in Advanced Parkinson's Disease: A UK Case Series |
| title_short | Impact of Duodopa on Quality of Life in Advanced Parkinson's Disease: A UK Case Series |
| title_sort | impact of duodopa on quality of life in advanced parkinson s disease a uk case series |
| url | http://dx.doi.org/10.1155/2013/362908 |
| work_keys_str_mv | AT tfoltynie impactofduodopaonqualityoflifeinadvancedparkinsonsdiseaseaukcaseseries AT cmagee impactofduodopaonqualityoflifeinadvancedparkinsonsdiseaseaukcaseseries AT cjames impactofduodopaonqualityoflifeinadvancedparkinsonsdiseaseaukcaseseries AT gjmwebster impactofduodopaonqualityoflifeinadvancedparkinsonsdiseaseaukcaseseries AT ajlees impactofduodopaonqualityoflifeinadvancedparkinsonsdiseaseaukcaseseries AT plimousin impactofduodopaonqualityoflifeinadvancedparkinsonsdiseaseaukcaseseries |